Reported Earnings • May 15
First quarter 2026 earnings released: EPS: NT$0.39 (vs NT$1.26 in 1Q 2025) First quarter 2026 results: EPS: NT$0.39 (down from NT$1.26 in 1Q 2025). Revenue: NT$214.5m (down 8.2% from 1Q 2025). Net income: NT$13.3m (down 66% from 1Q 2025). Profit margin: 6.2% (down from 17% in 1Q 2025). The decrease in margin was primarily driven by lower revenue. Buy Or Sell Opportunity • Apr 23
Now 22% undervalued after recent price drop Over the last 90 days, the stock has fallen 32% to NT$58.50. The fair value is estimated to be NT$74.85, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 13% over the last 3 years. Earnings per share has grown by 23%. Buy Or Sell Opportunity • Apr 07
Now 20% undervalued after recent price drop Over the last 90 days, the stock has fallen 28% to NT$59.80. The fair value is estimated to be NT$74.85, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 13% over the last 3 years. Earnings per share has grown by 23%. Reported Earnings • Mar 15
Full year 2025 earnings released: EPS: NT$5.29 (vs NT$5.43 in FY 2024) Full year 2025 results: EPS: NT$5.29. Revenue: NT$1.04b (up 5.0% from FY 2024). Net income: NT$176.0m (up 3.4% from FY 2024). Profit margin: 17% (in line with FY 2024). Declared Dividend • Mar 14
Dividend reduced to NT$3.00 Dividend of NT$3.00 is 14% lower than last year. Ex-date: 27th March 2026 Payment date: 28th April 2026 Dividend yield will be 4.2%, which is higher than the industry average of 2.6%. Sustainability & Growth Dividend is covered by earnings (73% earnings payout ratio) but the company has no free cash flows available, indicating it may be using cash reserves or debt to pay the dividend. The dividend has increased by an average of 54% per year over the past 2 years and payments have been stable during that time. Earnings per share has grown by 8.8% over the last 5 years. Unless this trend reverses, it should provide support to the dividend and adequate earnings cover. Aankondiging • Mar 13
Synbio Tech Inc. announces Annual dividend, payable on April 28, 2026 Synbio Tech Inc. announced Annual dividend of TWD 3.0000 per share payable on April 28, 2026, ex-date on March 27, 2026 and record date on March 30, 2026. Aankondiging • Mar 12
Synbio Tech Inc., Annual General Meeting, May 29, 2026 Synbio Tech Inc., Annual General Meeting, May 29, 2026, at 09:00 Taipei Standard Time. Location: no,23, lu k`o 5th rd., lujhu district, kaohsiung city Taiwan Buy Or Sell Opportunity • Mar 11
Now 20% undervalued after recent price drop Over the last 90 days, the stock has fallen 23% to NT$69.60. The fair value is estimated to be NT$87.33, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 14% over the last 3 years. Earnings per share has grown by 26%. Board Change • Mar 02
Less than half of directors are independent Following the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 4 non-independent directors. Director Zhao-Ming Liu was the last director to join the board, commencing their role in 2023. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. New Risk • Nov 21
New minor risk - Market cap size The company's market capitalization is less than US$100m. Market cap: NT$3.12b (US$99.2m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (14% operating cash flow to total debt). High level of non-cash earnings (29% accrual ratio). Minor Risks Paying a dividend despite having no free cash flows. Share price has been volatile over the past 3 months (7.0% average weekly change). Market cap is less than US$100m (NT$3.12b market cap, or US$99.2m). New Risk • Nov 12
New major risk - Financial position The company's debt is not well covered by operating cash flow. Operating cash flow to total debt ratio: 18% This is considered a major risk. If the company's operating cash flows are too small relative to the size of their debt, it increases their balance sheet risk. The company has less cash from operations to cover its expenses from servicing large debt and it increases the risk of liquidity issues. It also extends the time it would take for the company to pay back the debt in full, meaning it may not be able to easily pay it all off in a distress scenario. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (18% operating cash flow to total debt). High level of non-cash earnings (30% accrual ratio). Minor Risks Paying a dividend despite having no free cash flows. Share price has been volatile over the past 3 months (7.2% average weekly change). Reported Earnings • Nov 12
Third quarter 2025 earnings released: EPS: NT$0.92 (vs NT$1.81 in 3Q 2024) Third quarter 2025 results: EPS: NT$0.92 (down from NT$1.81 in 3Q 2024). Revenue: NT$211.3m (down 23% from 3Q 2024). Net income: NT$31.8m (down 44% from 3Q 2024). Profit margin: 15% (down from 21% in 3Q 2024). The decrease in margin was driven by lower revenue. Valuation Update With 7 Day Price Move • Aug 25
Investor sentiment improves as stock rises 15% After last week's 15% share price gain to NT$131, the stock trades at a trailing P/E ratio of 24.9x. Average forward P/E is 22x in the Biotechs industry in Taiwan. Total returns to shareholders of 64% over the past year. Reported Earnings • Aug 12
Second quarter 2025 earnings released: EPS: NT$1.92 (vs NT$1.74 in 2Q 2024) Second quarter 2025 results: EPS: NT$1.92 (up from NT$1.74 in 2Q 2024). Revenue: NT$309.1m (up 28% from 2Q 2024). Net income: NT$62.6m (up 15% from 2Q 2024). Profit margin: 20% (down from 23% in 2Q 2024). The decrease in margin was driven by higher expenses. New Risk • Jul 22
New major risk - Earnings quality The company has a high level of non-cash earnings. Accrual ratio: 22% This is considered a major risk. Non-cash earnings can arise from many different things. However, if a company consistently has a high level of non-cash earnings, it may be a sign that they are recognizing revenue from customers before the full value of the sales are received as cash or they are not depreciating the value of their assets appropriately. These are practices that inflate earnings, while not providing a similar increase to cash flows. Companies in some select industries naturally have a high level of non-cash earnings and it is not a major concern. However, in the worst case scenario it can be an early sign of performance manipulation by management. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (11% average weekly change). High level of non-cash earnings (22% accrual ratio). Minor Risk High level of debt (42% net debt to equity). New Risk • May 29
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Taiwanese stocks, typically moving 9.0% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk No financial data reported. Minor Risks Share price has been volatile over the past 3 months (9.0% average weekly change). Market cap is less than US$100m (NT$2.57b market cap, or US$86.0m). Aankondiging • May 08
Synbio Tech Inc. has filed a Follow-on Equity Offering. Synbio Tech Inc. has filed a Follow-on Equity Offering.
Security Name: Shares
Security Type: Common Stock
Securities Offered: 2,122,000
Price(minimum): TWD 46.31
Security Name: Shares
Security Type: Common Stock
Securities Offered: 560,000
Price\Range: TWD 56.5
Transaction Features: Subsequent Direct Listing New Risk • Apr 07
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Taiwanese stocks, typically moving 6.7% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk No financial data reported. Minor Risks Share price has been volatile over the past 3 months (6.7% average weekly change). Market cap is less than US$100m (NT$1.93b market cap, or US$58.3m). New Risk • Nov 06
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Taiwanese stocks, typically moving 6.8% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk No financial data reported. Minor Risks Share price has been volatile over the past 3 months (6.8% average weekly change). Market cap is less than US$100m (NT$2.62b market cap, or US$80.9m). Aankondiging • Apr 05
Synbio Tech Inc., Annual General Meeting, Jun 27, 2024 Synbio Tech Inc., Annual General Meeting, Jun 27, 2024. Aankondiging • Apr 04
SYNPET, Subsidiary Brand of SYNBIO TECH Announces to Showcase Innovative Postbiotic Solutions at Petfood Forum 2024 SYNPET, a subsidiary brand of SYNBIO TECH announced its participation at the upcoming Petfood Forum 2024. This premier event for pet food and pet treat manufacturers and industry suppliers will take place from April 29, 2024 to May 1, 2024 at the Kansas City Convention Center in Kansas City, Missouri, USA. At Petfood Forum 2024, SYNPET will showcase its headlining product: GABA 20: A postbiotic designed for pets to boost immunity, reduce stress and aggressive behavior. Produced through lactic acid bacteria fermentation, SYNPET's GABA has high bioavailability and boasts a purity over 20%, offering stability for easy processing into various formats such as capsules, powder, and pet food formulations. 
